Japan 2018 Review: Takeda/Shire Dominates But Pharma Life Goes On
Executive Summary
2018 in Japan wasn't all about Takeda and Shire - though it mostly was. Amid a generally quiet year for M&A otherwise, companies concentrated on honing their specialty focus, dealing with major patent expiries, and fretting about big changes to the country's pricing system.